Takeda (TKPYY) is seeking to divest $10B of assets after completing a GBP46B deal to buy Shire (SHPG), The Financial Times reports. CEO Christophe Weber says Nycomed is among the company’s “non-core assets” that it could consider selling. Looking ahead, Takeda will focus on five core areas: oncology, gastrointestinal conditions, neuroscience, rare diseases and plasma-derived therapies
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.